Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants
Meister T, Nocke M, Heinen N, Burkard T, Brüggemann Y, Westhoven S, Trüeb B, Ebert N, Thomann L, Lubieniecki K, Lubieniecka J, Döring K, Herrmann M, Haid S, Pietschmann T, Wiegmann B, Tao R, Pfefferle S, Addo M, Thiel V, Drexler I, Babel N, Phuc Nguyen H, Brown R, Todt D, Steinmann E, Pfaender S
Published in
Proceedings of the National Academy of Sciences of the United States of America: Volume 122, Issue 28, Page e2500276122
Abstract
Mycophenolic acid (MPA) is commonly used in immunosuppressive regimens following solid organ transplantation. We demonstrate that MPA treatment reproducibly inhibits the replication of a range of viruses, including severe respiratory syndrome coronavirus 2 (SARS-CoV-2). Mechanistically, we identified cellular guanosine triphosphate pool depletion as a key mediator of this antiviral effect. Strikingly, this inhibition can be overcome which was correlated with the emergence of three breakthrough mutations in the SARS-CoV-2 genome (S P812R, ORF3 Q185H, and E S6L). Subsequent analyses confirmed that the combination of these mutations conferred accelerated replication kinetics, higher viral titers, and more rapid onset of cytopathic effects, but not MPA resistance. Comparison of global transcriptional responses to infection highlighted dysregulation of specific cellular gene programs under MPA treatment prior to breakthrough mutation emergence. Together, these findings identify viral and host drivers of variant emergence under immunosuppression. They also advocate for close monitoring of immunosuppressed patients, where emergence of novel viral variants with a fitness advantage may arise.
Open in PubMed